Sexual dysfunction in patients with schizophrenia on antipsychotic medication

European Psychiatry

Volumn 22, Issue 5, 2007, Pages 328-333

  Üçok, Alp ^a   Incesu, Cem ^b   Aker, Tamer ^c   Erkoç, Şahap ^d  

^a ISTANBUL UNIVERSITY   (Turkey)

^b ACIBADEM HOSPITAL   (Turkey)

^c KOCAELI UNIVERSITY   (Turkey)

^d Bakirkoy State Hospital for Mental Health and Neurological Disorders   (Turkey)

Author keywords

ASEX; Atypical antipsychotics; Schizophrenia; Sexual dysfunction; Typical antipsychotics

Indexed keywords

ATYPICAL ANTIPSYCHOTIC AGENT; BIPERIDEN; BORNAPRINE; CHLORPROMAZINE; CHOLINERGIC RECEPTOR BLOCKING AGENT; CLOZAPINE; FLUPENTIXOL; HALOPERIDOL; NEUROLEPTIC AGENT; OLANZAPINE; QUETIAPINE; ZUCLOPENTHIXOL;

ADULT; AMENORRHEA; ARTICLE; CIGARETTE SMOKING; CONTROLLED STUDY; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DISEASE SEVERITY; ERECTILE DYSFUNCTION; FEMALE; HUMAN; INTERVIEW; LIBIDO; MAJOR CLINICAL STUDY; MALE; MENTAL PATIENT; MONOTHERAPY; ORGASM; OUTPATIENT; PREMATURE EJACULATION; PREVALENCE; PRIORITY JOURNAL; SCHIZOPHRENIA; SCORING SYSTEM; SEX DIFFERENCE; SEXUAL DYSFUNCTION; SEXUAL FUNCTION;

ADULT; ANTIPSYCHOTIC AGENTS; CROSS-SECTIONAL STUDIES; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; MALE; SCHIZOPHRENIA; SEXUAL DYSFUNCTION, PHYSIOLOGICAL; SMOKING; TURKEY;

EID: 34447625368     PISSN: 09249338     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.eurpsy.2007.01.001     Document Type: Article

References (39)

1. Aizenberg D., Modai I., Landa A., Gil-Ad I., and Weizman A. Comparison of sexual dysfunction in male schizophrenic patients maintained on treatment with classical antipsychotics versus clozapine. J Clin Psychiatry 62 (2001) 541-544
2. Aizenberg D., Zemishlany Z., Dorfman-Etrog P., and Weizman A. Sexual dysfunction in male schizophrenic patients. J Clin Psychiatry 56 (1995) 137-141
3. Alptekin K., Erkoc S., Gogus A.K., Kultur S., Mete L., Ucok A., et al. Disability in schizophrenia: clinical correlates and prediction over 1-year follow-up. Psychiatry Res 135 (2005) 103-111
4. Atmaca M., Kuloglu M., and Tezcan E. A new atypical antipsychotic: quetiapine-induced sexual dysfunctions. Int J Impot Res 17 (2005) 201-203
5. Balon R. Sexual function and dysfunction during treatment with psychotropic medications. J Clin Psychiatry 66 (2005) 1488-1499
6. Bobes J., Garc A-Portilla M.P., Rejas J., Hernandez G., Garcia-Garcia M., Rico-Villademoros F., et al. Frequency of sexual dysfunction and other reproductive side-effects in patients with schizophrenia treated with risperidone, olanzapine, quetiapine, or haloperidol: the results of the EIRE study. J Sex Marital Ther 29 (2003) 125-147
7. Byerly M.J., Lescouflair E., Weber M.T., Bugno R.M., Fisher R., Carmody T., et al. An open-label trial of quetiapine for antipsychotic-induced sexual dysfunction. J Sex Marital Ther 30 (2004) 325-332
8. Byerly M.J., Nakonezny P.A., Bettcher B.M., Carmody T., Fisher R., and Rush A.J. Sexual dysfunction associated with second-generation antipsychotics in outpatients with schizophrenia or schizoaffective disorder: an empirical evaluation of olanzapine, risperidone, and quetiapine. Schizophr Res 86 (2006) 244-250
9. Byerly M.J., Nakonezny P.A., Fisher R., Magouirk B., and Rush A.J. An empirical evaluation of the Arizona sexual experience scale and a simple one-item screening test for assessing antipsychotic-related sexual dysfunction in outpatients with schizophrenia and schizoaffective disorder. Schizophr Res 81 (2006) 311-316
10. Cutler A.J. Sexual dysfunction and antipsychotic treatment. Psychoneuroendocrinology 1 Suppl (2003) 69-82
11. Dossenbach M., Dyachkova Y., Pirildar S., Anders M., Khalil A., Araszkiewicz A., et al. Effects of atypical and typical antipsychotic treatments on sexual function in patients with schizophrenia: 12-month results from the Intercontinental Schizophrenia Outpatient Health Outcomes (IC-SOHO) study. Eur Psychiatry 21 (2006) 251-258
12. Dossenbach M., Erol A., el Mahfoud Kessaci M., Shaheen M.O., Sunbol M.M., Boland J., et al. IC-SOHO Study Group Effectiveness of antipsychotic treatments for schizophrenia: interim 6-month analysis from a prospective observational study (IC-SOHO) comparing olanzapine, quetiapine, risperidone, and haloperidol. J Clin Psychiatry 65 (2004) 312-321
13. Gades N.M., Nehra A., Jacobson D.J., McGree M.E., Girman C.J., Rhodes T., et al. Association between smoking and erectile dysfunction: a population-based study. Am J Epidemiol 161 (2005) 346-351
14. Goodnick P.J., Rodriguez L., and Santana O. Antipsychotics: impact on prolactin levels. Expert Opin Pharmacoter 3 (2002) 1381-1391
15. Guy W (ed). Clinical global impressions (CGI). In: ECDEU assessment manual for psychopharmacology. US Department of Health and Human Services, Public Health Service, Alcohol Drug Abuse and Mental Health Administration, NIMH Psychopharmacology Research branch; 1976. p. 218-22.
16. Hummer M., Kemmler G., Kurz M., Kurzthaler I., Oberbauer H., and Fleischhacker W.W. Sexual disturbances during clozapine and haloperidol treatment for schizophrenia. Am J Psychiatry 156 (1999) 631-633
17. Jayaram M.B., and Hosalli P. Risperidone versus olanzapine for schizophrenia. Cochrane Database Syst Rev 18 2 (2005) CD005237
18. Kelly D.L., and Conley R.R. Sexuality and schizophrenia: a review. Schizophr Bull 30 (2004) 767-779
19. Kim K.S., Pae C.U., Chae J.H., Bahk W.M., Jun T.Y., Kim D.J., et al. Effects of olanzapine on prolactin levels of female patients with schizophrenia treated with risperidone. J Clin Psychiatry 63 (2002) 408-413
20. Kleinberg D.L., Davis J.M., de Coster R., Van Baelen B., and Brecher M. Prolactin levels and adverse events in patients treated with risperidone. J Clin Psychopharmacol 19 (1999) 57-61
21. Knegtering H., Boks M., Blijd C., Castelein S., van den Bosch R.J., and Wiersma D. A randomized open-label comparison of the impact of olanzapine versus risperidone on sexual functioning. J Sex Marital Ther 32 (2006) 315-326
22. Knegtering R., Castelein S., Bous H., Van Der Linde J., Bruggeman R., Kluiter H., et al. A randomized open-label study of the impact of quetiapine versus risperidone on sexual functioning. J Clin Psychopharmacol 24 (2004) 56-61
23. Kockott G., and Pfeiffer W. Sexual disorders in nonacute psychiatric outpatients. Compr Psychiatry 37 (1996) 56-61
24. Lambert M., Conus P., Eide P., Mass R., Karow A., Moritz S., et al. Impact of present and past antipsychotic side effects on attitude toward typical antipsychotic treatment and adherence. Eur Psychiatry 19 (2004) 415-422
25. Lambert M., Haro J.M., Novick D., Edgell E.T., Kennedy L., Ratcliffe M., et al. Olanzapine vs other antipsychotics in actual out-patient settings: six months tolerability results from the European Schizophrenia Out-patient Health Outcomes study. Acta Psychiatr Scand 111 (2005) 232-243
26. Lingjaerde O., Ahlfors U.G., Bech P., Dencker S.J., and Elgen K. The UKU side effect rating scale. A new comprehensive rating scale for psychotropic drugs and a cross-sectional study of side effects in neuroleptic-treated patients. Acta Psychiatr Scand 334 Suppl. (1987) 1-100
27. Macdonald S., Halliday J., MacEwan T., Sharkey V., Farrington S., Wall S., et al. Nithsdale Schizophrenia Surveys 24: sexual dysfunction. Case-control study. Br J Psychiatry 182 (2003) 50-56
28. McGahuey C.A., Gelenberg A.J., Laukes J.A., Moreno F.A., Delgado P.L., McKnight K.M., et al. The Arizona Sexual Experience Scale (ASEX). Reliability and validity. J Sex Marital Ther 26 (2000) 25-40
29. Montejo Gonzalez A.L., Rico-Villademoros F., Tafalla M., Majadas S., and Spanish Working Group for the Study of Psychotropic-Related Sexual Dysfunction. A 6-month prospective observational study on the effects of quetiapine on sexual functioning. J Clin Psychopharmacol 25 (2005) 533-538
30. Naber D., Karow A., and Lambert M. Subjective well-being under the neuroleptic treatment and its relevance for compliance. Acta Psychiatr Scand Suppl 427 (2005) 29-34
31. Olfson M., Uttaro T., Carson W.H., and Tafesse E. Male sexual dysfunction and quality of life in schizophrenia. J Clin Psychiatry 66 (2005) 331-338
32. Perkins D.O. Predictors of noncompliance in patients with schizophrenia. J Clin Psychiatry 63 (2002) 1121-1128
33. Salokangas R.K., Honkonen T., Stengard E., Koivisto A.M., and Hietala J. Cigarette smoking in long-term schizophrenia. Eur Psychiatry 2 (2006) 219-223
34. Smith S.M., O'Keane V., and Murray R. Sexual dysfunction in patients taking conventional antipsychotic medication. Br J Psychiatry 181 (2002) 49-55
35. Stimmel G.L., and Gutierrez M.A. Sexual dysfunction and psychotropic medications. CNS Spectr 11 8 Suppl. 9 (2006) 24-30
36. Teusch L., Scherbaum N., Bohme H., Bender S., Eschmann-Mehl G., and Gastpar M. Different patterns of sexual dysfunctions associated with psychiatric disorders and psychopharmacological treatment. Results of an investigation by semistructured interview of schizophrenic and neurotic patients and methadone-substituted opiate addicts. Pharmacopsychiatry 28 (1995) 84-92
37. Ucok A., Polat A., Bozkurt O., and Meteris H. Cigarette smoking among patients with schizophrenia and bipolar disorders. Psychiatry Clin Neurosci 58 (2004) 434-437
38. Volavka J., Czobor P., Cooper T.B., Sheitman B., Lindenmayer J.P., Citrome L., et al. Prolactin levels in schizophrenia and schizoaffective disorder patients treated with clozapine, olanzapine, risperidone, or haloperidol. J Clin Psychiatry 65 (2004) 57-61
39. Zhong K.X., Sweitzer D.E., Hamer R.M., and Lieberman J.A. Comparison of quetiapine and risperidone in the treatment of schizophrenia: a randomized, double-blind, flexible-dose, 8-week study. J Clin Psychiatry 67 (2006) 1093-1103